Ferriprox Oral Solution
Generic name:deferiprone
Dosage form: oral solution
Drug classes:Antidotes, Chelating agents
Medically reviewed by Drugs.com. Last updated on Nov 1, 2021.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Medication Guide
WARNING: AGRANULOCYTOSIS AND NEUTROPENIA
- FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.[see Warnings and Precautions (5.1)]
- Measure the absolute neutrophil count (ANC) before starting FERRIPROX therapy and monitor regularly while on therapy.[see Warnings and Precautions (5.1)]
- Interrupt FERRIPROX therapy if neutropenia develops.[see Warnings and Precautions (5.1)]
- Interrupt FERRIPROX if infection develops, and monitor the ANC more frequently.[see Warnings and Precautions (5.1)]
- Advise patients taking FERRIPROX to report immediately any symptoms indicative of infection.[see Warnings and Precautions (5.1)]
1 INDICATIONS AND USAGE
Ferriprox Oral Solution is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.
Limitations of Use
- Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.
